FDA approves Gilead’s Bixlenvo as single-tablet HIV option for patients on complex regimens

The once-daily combination of bictegravir and lenacapavir offers virologically suppressed adults a new route to simplify treatment, including patients previously requiring complex multi-tablet regimens.

The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) as a complete regimen for adults with HIV-1 who are virologically suppressed on stable antiretroviral therapy and have no known or suspected resistance to its individual components.

Bixlenvo becomes the first and only single-tablet regimen for most virologically suppressed patients on complex HIV treatment regimens who cannot use currently available single-tablet options, combining bictegravir with the first-in-class capsid inhibitor lenacapavir.

Field	Content
Alert Type	Drug Approval
Drug Name	Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg)
Indication	Complete regimen to replace current antiretroviral therapy in adults with HIV-1 who are virologically suppressed, with HIV-1 RNA below 50 copies/mL, on a stable regimen and with no known or suspected resistance to Bixlenvo’s individual components
Therapy Area(s)	Infectious disease; HIV
Geography	United States (FDA)
What Happened	On 27 August 2026, the FDA approved Gilead’s Bixlenvo, a once-daily single-tablet combination of bictegravir and lenacapavir. The treatment pairs bictegravir, an integrase strand transfer inhibitor (INSTI), with lenacapavir, a first-in-class capsid inhibitor with no cross-resistance to existing antiretroviral classes. Bixlenvo requires a two-day initiation regimen involving oral Sunlenca (lenacapavir), followed by one Bixlenvo tablet daily from day three onwards. (Gilead Sciences Investor Relations)
Why It Matters	Single-tablet HIV regimens have simplified treatment for many patients, but some people with resistance, tolerability issues, contraindications or drug interactions still require complex combinations. Bixlenvo provides a new simplification option for virologically suppressed adults, including treatment-experienced patients who previously required multiple tablets or more than once-daily dosing. (Gilead Sciences Investor Relations)
Supporting Context	Approval was supported by the Phase III ARTISTRY-1 and ARTISTRY-2 trials. Both showed Bixlenvo was comparable to the control regimens in maintaining virologic suppression through week 48. ARTISTRY-1 specifically studied highly treatment-experienced patients: participants had been treated for a median 28 years, 67% had historical NRTI resistance and some were taking as many as 11 pills per day before switching. (Gilead)
Safety	Bixlenvo was generally well tolerated in the ARTISTRY programme, with no significant or new safety concerns identified. The most commonly reported adverse reactions were headache, nausea and diarrhoea. (Gilead Sciences Investor Relations)
Key Takeaway	Bixlenvo extends the benefits of once-daily single-tablet HIV therapy to a broader group of virologically suppressed adults, particularly treatment-experienced patients whose resistance or treatment history has previously required more complicated antiretroviral regimens.
What to Watch	Uptake among treatment-experienced patients and further expansion of Gilead’s lenacapavir-based HIV portfolio. Gilead and Merck are separately developing islatravir/lenacapavir as a once-weekly oral HIV regimen, with Phase III studies having maintained virologic suppression through week 48 and regulatory submissions planned. (Gilead Sciences Investor Relations)
Primary Source	Gilead Sciences
Relevant Date	27 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com